Ironwood Pharmaceuticals, Inc. (IRWD) NASDAQ
3.28
-0.18(-5.20%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
3.28
-0.18(-5.20%)
Currency In USD
Address
100 Summer Street
Boston, MA 02110
United States of America (the)
Phone
617 621 7722
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
253
First IPO Date
February 03, 2010
| Name | Title | Pay | Year Born |
| Thomas A. McCourt | Chief Executive Officer & Director | 1.54M | 1957 |
| John Minardo | Senior Vice President, Chief Legal Officer & Secretary | 717,470 | 1976 |
| Michael Shetzline | Chief Medical Officer, Senior Vice President and Head of Research & Drug Development | 756,701 | 1959 |
| Greg Martini | Senior Vice President, Chief Financial Officer & Investor Relations | 763,356 | 1989 |
| Tammi Gaskins | Senior Vice President & Chief Commercial Officer. | 767,612 | 1973 |
| Jeff Ruberti | Chief Strategy Officer | 0 | N/A |
| Rosario Lobrutto | Vice President & Global Head of Technical Operations | 0 | N/A |
| Ronald Silver | Senior VP, Interim CFO, Corporate Controller & Chief Accounting Officer | 0 | 1982 |
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.